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INTRAGASTRIC administration of a single 20 mg. dose of 7,12-dimethyl-
benz(a)anthracene (DMBA) in sesame oil to female Sprague-Dawley rats results
in rapid induction of mammary carcinoma (Huggins, Grand and Brillantes, 1961;
Huggins and Yang, 1962). This process, as well as the induced tumours, was
found by many investigators to be highly sensitive to the hormonal status of the
animals. The role of the ovarian hormones was investigated by Dao (1962).
The effect of pregnancy was studied by Huggins, Moon and Morii (1962) and by
McCormick and Moon (1965), and that of androgens by Young, Baker and
Helfenstein (1965). The relationship of the pituitary was a subject of study bv
Sterental, Dominguez, Weissman and Pearson (1963) and by Dao (1964).
The present study deals with the effect of relaxin, the non-steroid ovarian
hormone, upon the process of DMBA mammary carcinogenesis. Also the uptake
and clearance of the carcinogen in rat mammary tissue were investigated.
The existence of relaxin was first suspected by Hisaw (1926) and was demon-
strated to be the factor responsible for relaxation of the symphysis pubis in
pregnant guinea-pigs. It was extracted from the corpora lutea of pregnant sows
by Fevold, Hisaw and Meyer (1930). Subsequently, it was detected in a wide
variety of mammals, including women, reaching its highest concentration during
pregnancy (Steinetz, Beach and Kroc, 1959; Zarrow, Holmstrom and Salhanick,
1955). Among other effects, this hormone was found to stimulate mammarv
gland development in a variety of laboratory animals, including rats (Hamolsky
and Sparrow, 1945; Smith, 1954; Garrett and Talmage, 1952). This was con-
firmed later by Wada and Turner (1958, 1959) using whole mount preparations
of. and DNA determinations in, mammary tissue.
The ovaries of pregnant sows are the main source of relaxin preparations.
It is precipitated by acetone from saline and ethanol tissue extracts, dialyzed
and lyophilized (Frieden and Hisaw, 1953). Further purification can be obtained
bv butanol and trichloroacetic acid mixture (Frieden and Layman, 1957).
MATERIALS AND METHODS
Anirnals
All were intact, virgin, female Sprague-Dawley rats, 50-52 days of age at the
time of DMBA administration. They were maintained on a standard laboratory
diet of ' Master Fox Cubes "* (Maple LeafMills Ltd., Toronto, Ontario) and water
ad libitum.
* Standard laboratory diet: " MasterFox C0ubes ' Brew-ers dried yeast, dried beet pulp, dehydrated
alfalfa meal, fish meal, animals' liver meal, cooked corn flakes, cooked wheat flakes, wheat bran,
wheat germ, dicalcium phosphate, potassium iodide, ground limestone, 5% iodized salt, manganese
sulphate, iron sulphate, vitamins A and B supplement, riboflavin, vitamin E. Crude protein 20%,
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Each rat received 20 mg. of DMBA dissolved in 1 ml. of sesame oil in a single
dose, by gastric intubation. Thereafter, the animals were weighed and palpated
for tumours twice a week. Tumours were measured in 2 diameters with calipers
and the measurements recorded to the closest millimeter.
All animals were observed for approximately 5 months. However, due to
tumour ulceration some of the rats had to be killed earlier. At autopsy, tumours
were identified and resected and, together with suspicious subcutaneous lesions,
they were processed for microscopical examination. All diagnoses were thus
based on histological criteria.
Relaxin
Since comnplete purification of the hormone has not yet been achieved, as
shown by starch gel electrophoresis, the term " relaxin " or " relaxin extract "
used throughout this article, refers to that water soluble extract of sow's ovarian
tissue which will elicit relaxation of the symphysis pubis in the guinea-pig and
mouse. The extracts used were provided in powder form by Warner-Lambert
Research Institute in Morris Plains, N.J.. research affiliate of Warner-Chilcott
Laboratories.
One preparation (Wi 164, lot 48E-1105a), extracted from ovaries of pregnant
sows, assayed at 150 guinea-pig units (G.P.U.)/1 mg. powder, is referred to in this
study as " high potency relaxin ".
The other preparation (WI164, lot 565/1C), extracted from ovaries of non-
pregnant sows, assayed at 0 5 G.P.U./1 mg. powder, is referred to as " low potency
relaxin ", and was used to run parallel control study groups for possible vehicle
and non-specific polypeptide effects.
The extracts were injected subcutaneously, suspended in 500 beeswax in sesame
oil.
Specific doses and schedules of relaxin treatment will be mentioned during the
presentation of results.
Quantitative estimation of D)IMBA in mammary tissue
This was done at intervals of 3, 6. 12, 24, 48, 72, and 120 hours following the
administration of 20 mg. of carcinogen in 1 ml. of sesame oil to female rats similar
to the ones used for cancer induction. The method was a combination of thin-
layer and gas-liquid chromatography and was published by Gammal. Carroll.
Muhlstock, and Plunkett (1965).
RESULTS
Most of the tumours induced by DMBA were malignaint tumours of epithelial
origin, i.e., adenocarcinomas; the observations that follow are confined to this
type of tumour. In all cases the malignant character of the tumours was
confirmed histologically.
Relaxin and mammary carcinogenesis
The purpose of this study was two-fold: To demonstrate any effect of relaxin
and to determine whether this effect differed according to the time of relaxin
administration in relation to IDMBA feeding.
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Relaxin treatment started before DMBA (Table I)
In these experiments treatment with relaxin extracts was started 1 week before
DMBA administration and continued for a total period of 7 weeks. 1 mg. of
either potency, in 0 05 ml. of beeswax in sesame oil, was injected 3 times a week.
TABLE L.-Effect ofRelaxin Treatment Beginning 1 Week Before
DMBA Administration*
% Tumour No. No.
No. of bearing tumourst/rat tumourst/tumour Latent periodt
Treatment rats rats (total group) bearing rat (days)
1. Nil 42 . 69*0 18 ±0-27 . 2-5 ±027 . 87-6 6-1
2. Relaxin
Low potency . 32 . 75.0 . 2-0 ± 041 . 2-7 ± 0-48 96.4 ± 6-98
3. Relaxin
High potency . 33 . 33-3 . 0 7 + 02 . 2-1 ± 0-31 . 94-8 i 111
"P " values for
groups I and3. . < 001 . < 001
"P " values for
groups2and3. . <001 <001
* All rats received 20 mg. of DMBA in 1 ml. of sesame oil by stomach tube.
tMean ± S.E.M.
Sixty-nine per cent ofthe animals in the control group, which was not injected,
developed mammary tumours. Treatment with low potency relaxin extract
gave essentially the same incidence. However, in animals treated with high
potency extract this incidence was reduced to 33.3%. The difference was signifi-
cant at the 1% level. This was also illustrated by the number of tumours per
rat when all of the animals in each group were taken into consideration. How-
ever, when the comparison was confined to tumour-bearing rats there was no
significant difference inthe number oftumours per animal in the 3 different groups,
neither was the latent period significantly affected by this type of treatment.
When tumour size permitted, measurements were begun in all 3 groups and
the results are represented for the next 6 week period in Fig. 1. Each point
represents the average total tumour area per rat in mm2. It is evident from this
graph that the growth rate of tumours in the high potency relaxin treated rats
was not significantly different from that ofthe 2 control groups. This observation
was confirmed by a statistical analysis of the average differences in tumour size
between day 1 and day 43 one time and between day 1 and day 22 another time
Relaxin treatment started after DMBA (Table II)
Inthese experiments relaxintreatmentwas delayedfor 6weeks aftercarcinogen
feeding. The amount of injected extracts, the volume of vehicle, the frequency
and duration of treatment were all identical to those mentioned above.
The incidence of DMBA-induced mammary tumours, expressed as percentage
of rats bearing tumours, was not significantly affected by this treatment. The
100% incidence in the low potency relaxin treated group was probably an apparent
rather than a true increase due to the relatively small effective number ofanimals
in this particular group. This was also confirmed by a lack of statistical
significance.
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When the average number of tumours per rat in the 3 different groups was
compared, a trend could be observed pointing to an increase in the high potency
relaxin treated group over the other 2 groups. This trend was maintained when
the comparison was made between the average number of tumours per tumour-
bearing rat. In this instance, the mean number of tumours per animal in the
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FiG. I. Effect of ielaxin extracts on growth rate of DMBA-induced mammary tumours.
Relaxin treatment started one week before DMBA administration.
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TABLE II.-Effect of Relaxin Treatment Beginning 6 Weeks After
DMBA Administration*
No. of
Treatment rats
1. Nil 43
2. Relaxin
Low potency 12
3. Relaxin
High potency . '
" P " values for
groups 1 and 3 .
" P " values for
groups 2 and 3 .
0O Tumour
hearing
rats
69-8
No.
tumourst/rat
(total group)
1-8 ± 0-27
No.
tumourst/tumour
bearing rat
2).5 ± 0-30
10(0 2-6 ± 0-46 . 2-6 -4- 0-46
81-8 2-9 0-53 3-6 ± 0.52
< 0 05
> 0 6
< 0 0.5
>0-1
Latent periodt
(days)
88-0 6-06
93-2 ± 7-10
69-1 5-21
< 0-05
<0 02
* All rats received 20 mg. of DMBA in 1 ml. of sesame oil by stomach tube.
t Mean ± S. E. M.
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high potency treated group was significantly greater than that of the untreated
controls, but not when compared with the low potency treated group. This latter
may be related to the comparatively small number of animals in the " lom
potency " treated group.
The average latent period was found to be significantly shorter in the high
potency relaxin treated animals when compared with that of the 2 control groups,
denoting once more an enhancing effect upon mammary tumour formation.
The growth rate of tumours in these 3 groups of animals is shown in Fig. 2.
It is apparent from this figure that in high potency relaxin treated rats tumour
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FIC. 2.- Effect of relaxin extracts on growth rate of DMBA-induced mammary tumours.
Relaxin treatment started six weeks after DMBA administration.
growth was more rapid than in each of the control groups. Statistical analysis
of the average differences in tumour size between day 1 and day 29 one time and
day 1 and day 43 another time showed that tumour growth rate in each of the 2
control groups was essentially similar. However, both were significantly different
from that of the high potency extract treated group.
The above mentioned effects of high and low potency relaxin treatment upon
DMBA mammary carcinogenesis were combined in Table III. Treatment with
high potency extract, when started before carcinogen feeding, is compared with
the post carcinogen treated group (upper part of table). The former group
exhibited a significantly lower incidence of tumour bearing rats, fewer tumours
and a longer latent period.EFFECT OF RELAXIN ON MAMMARY CANCER
TABLE III.-Fffects ofStarting Time of Relaxin Treatment Upon
DMBA Mammary Carcinogenesis
% Tumour No. No.
No. of bearing tumours*/rat tumours*/tumour Latent, perio(d*
Treatment rats rats (total group) bearing rat (days)
1. Relaxin
High potency 33 33-3 07 ± 0-2 21 4- 0-31 94 8 ± 11 1
2. Relaxin
High potency 2 81-8 29 ± 0-53 3-6 0-52 69-1 5-21
"P " values for the
above 2 groups - < 001 < 0001 < 005 <005
1. Relaxin
Low potency 32 75 0 20 ± 0-41 2-7 0-48 964 ± 6-98
2. Relaxin
Low potency 12 1000 26 ± 0-46 2-6 0-46 93 2 7-10
"P " values for the
above 2 groups . . >0 1 > 0 4
* Mean ± S. E. M.
1. Treatment started 1 week before DMBA administration.
2. Treatment started 6 weeks after DMBA administration.
However, a comparison between the 2 low potency extract treated groups
(lower part of table) showed no significant difference in the incidence, number or
latent period of the tumours induced.
Relaxin and DMBA in breast tissue
The uptake and clearance of DMBA by rat mammary tissue are graphically
represented in Fig. 3. Each point on the graph represents the average of 6-8
determinations, except for the 72 and 120-hour intervals each of which is based
upon 5 estimations.
It is to be noted that the level of DMBA in the hormonally untreated group
rose sharply reaching a peak at 12 hours and then declined until at 5 days it
averaged 0 34 ,tg./g. of tissue.
In animals treated with three 1 mg. injections of high potency relaxin during
the week preceding DMBA administration, the level and rate of uptake and
clearance of carcinogen by the mammary tissue were not significantly different
from those of the above mentioned controls. The comparison was not carried
beyond the 24-hour interval (Table IV).
TABLE IV.-Concentration of DMBA in jg./g. Mammary Tissue
of Control and High Potency Relaxin Treated Rats
3 H 6 H 12 H 24 H 48 H 72 H 120 H
No hormoinal
treatme't 10-8 I- 2-41 12-4 1-94 14-6 4 3.30 10-5 + 1-47 4-6 0-67 2-3 0-65 0.34 -4 0-13
Relaxin
High
potency 14 3 ± 3 62 14 4 ± 098 15;7 2-05 10.0 ± 1-44 - -
"P values >0 4 > 0 3
H = Hours after DMBA administration.
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The actual mean values ofDMBA tissue concentration at the different intervals
studied, together with the standard error ofthe means for both control and relaxin
treated rats, are presented in Table IV. The difference between the average levels
of DMBA in the two groups was found to be insignificant.
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FIG. 3. Uptake and clearance of DMBA in mammary tissue of control and high potency
relaxin-treated rats. Relaxin treatment started one week before DMBA feeding. Within
the first 24 hours, DMBA levels were determined at 3-, 6-, 12- and 24-hour intervals.
H. POT. = High potency.
DISCUSSION
The data presented above demonstrated that DMBA mammary carcinogenesis
in intact female rats was influenced by relaxin treatment. Preliminary collabora-
tive studies reported by Cutts (1965), indicated that relaxin caused an increase
in growth rate and number of rat mammary tumours induced by oestrone pellets.
In the present investigation an additional control group treated with low potency
relaxin extract was included, in which the results were similar to those of the
untreated control group. Thus, the effects of treatment with high potency
extracts upon DMBA mammary carcinogenesis were probably those of relaxin
and not due to vehicle or to contaminants.
As shown in these experiments, when relaxin was started before DMBA
administration the nature of its effect was different from that observed when
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treatment was begun 6 weeks afterwards. Thus, 2 opposing effects ofthe hormone
were elicited which are quite reminiscent of the observations of Dao and Sunder-
land (1959), Dao, Bock and Greiner (1960) and McCormick and Moon (1965) on
the effects of pregnancy upon mammary tumorigenesis in rats. In their experi-
ments induction of mammary tumours with carcinogenic hydrocarbon was
inhibited in the pregnant animals as well as in those who became pregnant
immediately after carcinogen feeding. On the other hand, pregnancy occurring
in animals in which cancer had been previously induced enhanced tumour forma-
tion and growth.
These observed effects of pregnancy have been attributed to the marked
change in the hormonal status of the animal, particularly the high levels of
progesterone and oestrogens together with chorionic gonadotrophin. Relaxin,
however, was not considered as one of the hormones involved in such a change.
As previously mentioned, the concentration of this hormone is highest in pregnant
animals. In the rat for instance, the amount of relaxin was found to increase
from 2 to 720 G.P.U. per gram of ovarian tissue in the non-pregnant and pregnant
animal respectively (Steinetz et al., 1959). In view of these observations together
with the results of the present experiments, it is considered likely that relaxin is
one of the hormonal factors of pregnancy which affects mammary carcinogenesis.
Using the levels of DMBA in mammary tissue as an index of available carcino-
gen., we found no difference between relaxin treated and control animals. This
would suggest that the effect of the hormone, directly or indirectly, was on the
cell itself rather than on the amount of carcinogen to which it was exposed.
This is in agreement with a general conclusion of Bock and Dao (1961), that the
endocrine state ofthe rat had little effect upon the concentration of the carcinogen.
Although the present investigations did not attempt to elucidate the mechanism
of relaxin action, it would not be unreasonable to speculate that the observed
effect upon mammary carcinogenesis was indirectly via the pituitary. This is
based upon the observations of Wada and Turner (1958, 1959b) that relaxin treat-
ment did not stimulate mammary tissue growth in hypophysectomized mice,
while it was associated with significant increase in pituitary weight in intact rats.
Also, in his studies of the effect of relaxin upon oestrogen-induced breast cancer.
Cutts (1965) reported a 310% increase in pituitary weight in relaxin treated rats
compared to those bearing oestrone pellets only and observed that lactation
occurred in the former but not in the latter animals.
In the present experiments DMBA estimations were not made beyond 24 hours
after its administration to relaxin treated rats, mainly due to the scarcity of the
hormone. Also, because no previous studies were available concerning DMBA
mammary tissue levels within the first 24 hours and because our preliminary
experiments indicated the peak to occur within this time, investigation was
concentrated upon this interval. Other investigators using 3-methylcholanthrene
concluded that its peak concentration in rat mammary tissue was reached 24
hours following its oral administration (Dao et al., 1960; Bock and Dao, 1961),
no reference being made, however, to measurements at earlier intervals. In the
present studies the peak concentration of DMBA was found to occur 12 hours
after its administration.
SUMMARY
Mammary carcinogenesis by a single feeding of 7,12-dimethyl-benz(a)anthra-
cene in female rats was influenced by relaxin treatment. The starting time of
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relaxin treatment was found to determine the nature of its effect. When started
1 week before DMBA administration tumour induction was markedly inhibited.
However, the same dose and duration of relaxin treatment when begun 6 weeks
after DMBA administration resulted in promotion of tumour development and
growth. The similarity between these effects and those of pregnancy on induced
mammary tumorigensis was discussed, in view ofthe fact that relaxin is considered
to be a hormone of pregnancy; hence the possibility exists that it is one of the
factors by which the effects of pregnancy are mediated.
IDMBA concentration in mammary tissue of relaxin treated and control rats
was determined at different intervals during the first 24 hours after its administra-
tion. The uptake of the carcinogen was similar in both groups, suggesting that
relaxin did not alter the amount of hydrocarbon available in the tissue.
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